Table 3.
Cumulative incidence of adverse events (AEs) in the safety population by study week
| |
Donepezil 23–23 |
Donepezil 10–23 |
||||||
|---|---|---|---|---|---|---|---|---|
| |
N = 570 |
N = 332 |
||||||
| 1 week | 2 weeks | 4 weeks | 52 weeks (total duration) | 1 week | 2 weeks | 4 weeks | 52 weeks (total duration) | |
| Patients with at least 1 AE, % |
15.8 |
18.6 |
23.2 |
72.8 |
20.8 |
25.9 |
31.9 |
78.0 |
| Patients who discontinued due to AEs, % |
0.5 |
1.6 |
2.3 |
11.4 |
2.4 |
3.9 |
4.8 |
17.5 |
| Patients with AEs, % |
|
|
|
|
|
|
|
|
| Diarrhea |
0.4 |
0.4 |
0.9 |
3.5 |
1.5 |
2.1 |
2.7 |
5.7 |
| Nausea |
0.2 |
0.2 |
0.2 |
2.1 |
3.9 |
4.2 |
4.2 |
6.0 |
| Vomiting |
0.0 |
0.0 |
0.0 |
1.6 |
2.4 |
2.4 |
2.7 |
4.5 |
| Dizziness | 0.4 | 0.4 | 0.5 | 1.1 | 0.9 | 1.2 | 1.5 | 3.6 |